Foresee Pharmaceuticals Co., Ltd.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.foreseepharma.com
Clinical Trials
32
Active:11
Completed:13
Trial Phases
4 Phases
Phase 1:18
Phase 2:5
Phase 3:6
+1 more phases
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (31 trials with phase data)• Click on a phase to view related trials
Phase 1
18 (58.1%)Phase 3
6 (19.4%)Phase 2
5 (16.1%)Not Applicable
1 (3.2%)phase_2_3
1 (3.2%)Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)
Not Applicable
Not yet recruiting
- Conditions
- Asthma (Diagnosis)Pulmonary FunctionModerate-to-Severe Asthma
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Foresee Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT07191535
Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer
Phase 3
Withdrawn
- Conditions
- Prostate Cancer
- Interventions
- Drug: Triptorelin Mesylate
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Foresee Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT06795191
Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Foresee Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT06795178
Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD
Phase 2
Recruiting
- Conditions
- Group 3 Pulmonary Hypertension
- Interventions
- Drug: placebo
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- Foresee Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT06475781
- Locations
- 🇨🇳
Hualien Tzu Chi Hospital, Hualien City, Taiwan
🇨🇳Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Foresee Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT06334211
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
- Prev
- 1
- 2
- 3
- Next
News
No news found